

# Exploring the Development, Validity, and Utility of the Short-Form Version of the Choice of Outcome In Cbt for PsychosEs: A Patient-Reported Outcome Measure of Psychological Recovery

Rebecca Webb<sup>1</sup>, Gergely Bartl<sup>1</sup>, Bryony James<sup>1</sup>, Rosie Skan<sup>1</sup>, Emmanuelle Peters<sup>2,3</sup>, Anna-Marie Jones<sup>4</sup>, Philippa Garety<sup>2,5</sup>, Elizabeth Kuipers<sup>2,3,5</sup>, Mark Hayward<sup>1,4</sup>, and Kathryn Greenwood<sup>\*,1,4</sup>

<sup>1</sup>School of Psychology, University of Sussex, Pevensey 1, Falmer, Brighton BN1 9RH, UK; <sup>2</sup>Institute of Psychiatry, Psychology and Neuroscience, Department of Psychology, King's College London, London, UK; <sup>3</sup>Psychological Interventions Clinic for Outpatients With Psychosis, South London and Maudsley NHS Foundation Trust, Denmark Hill, London, UK; <sup>4</sup>R&D Department, Sussex Partnership NHS Foundation Trust, Brighton, UK; <sup>5</sup>National Institute for Health Research Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London, London, UK

\*To whom correspondence should be addressed; tel: +44 1273 678409, fax: +44 1273 678058, e-mail: [k.e.greenwood@sussex.ac.uk](mailto:k.e.greenwood@sussex.ac.uk)

The original Choice of Outcome In Cbt for psychosEs (CHOICE) measure was designed in collaboration with experts by experience as a patient-reported “Psychological Recovery” outcome measure for cognitive-behavioral therapy for psychosis (CBTp). A short version (CHOICE-SF) was developed to use as a brief outcome measure, with a focus on sensitivity to change, for use in future research and practice. CHOICE-SF was developed and validated using 3 separate samples, comprising 640 service users attending 1 of 2 transdiagnostic clinics for (1) CBTp or (2) therapies for voice hearing or (3) who took part in the treatment as usual arm of a trial. In the initial subsample of 69 participants, items from the original CHOICE measure with medium to large effect sizes for change pre- to post-CBTp were retained to form the CHOICE-SF. Internal consistency, construct validity, and sensitivity to change were confirmed, and the factor structure was examined in 242 participants. Specificity was confirmed by comparison with 44 participants who completed CHOICE at 2 time points but did not receive therapy. Validation of CHOICE-SF was carried out by confirming factor structure and sensitivity to change in a new sample of 354 and a subsample of 51 participants, respectively. The CHOICE-SF comprised 11 items and 1 additional personal goal item. A single-factor structure was confirmed, with high internal consistency, construct validity, and sensitivity to change. The CHOICE-SF is a brief, psychometrically robust measure to assess change following psychological therapies in research and clinical practice for people with psychosis and severe mental illness.

*Key words:* psychosis/patient-reported outcome measurement/psychological therapy/cognitive therapy

## Introduction

One of the key interventions for psychosis is cognitive-behavioral therapy.<sup>1</sup> Previous research examining the effectiveness of cognitive-behavioral therapy for psychosis (CBTp) has mainly focused on the reduction of psychosis symptoms using clinician-rated scales.<sup>2</sup> However, it has been argued that CBTp focuses on alternative outcomes that are not well captured by current measures.<sup>3,4</sup> Specifically, CBTp targets symptom-related distress and the impact on functioning, associated unhelpful thinking biases, and psychological and emotional recovery as opposed to symptom reduction.<sup>5,6</sup>

Furthermore, the goals of CBTp are agreed upon in collaboration with service users who have reported that other issues, such as empowerment, choice, control, and personal fulfillment, are of central concern.<sup>7</sup> CBTp, therefore, may address a variety of issues, such as negative beliefs about psychosis, self-esteem, self-stigma, self-confidence, and empowerment.<sup>8-11</sup>

As a result of this mismatch between CBTp aims and available measures, a new outcome measure of CBTp was developed and was designed to reflect both the priorities of CBTp and those of the service user (Choice of Outcome In Cbt for psychosEs [CHOICE]).<sup>12</sup> The initial measure was developed in collaboration with service user experts by experience through qualitative analysis and Delphi consultation to reach a consensus on the questionnaire items. The final measure was found to have 1 single factor, with good test-retest reliability, face and construct validity, and sensitivity to change.<sup>12</sup> Whilst constituting a single factor, the measure included both generic recovery-related items,

such as “feeling happy” and “a sense of being in control of my life,” and CBT-specific cognitive and coping items, such as “positive thinking,” “ways of dealing with unpleasant feelings and emotions,” and “ways of dealing with distressing experiences.” Since publication, the original CHOICE measure has been used in at least 4 randomized trials and 3 observational studies to assess the effectiveness of various psychological interventions, including mindfulness, structured communication, and relating therapy, as well as group-based, self-help and one-to-one CBT in individuals with psychosis experiences.<sup>13–19</sup> It has been referenced in recent policy documents<sup>20</sup> and has been adopted by routine clinical services in at least 10 National Health Service (NHS) trusts around the United Kingdom, as well as by UK clinical psychology training departments, and international services in Asia, America, and Europe, where it has been translated into other languages.<sup>21</sup> It has been described as an important measure of “self-defined recovery that may be valued more highly than symptom reduction alone by many service users.”<sup>4</sup>

The original CHOICE questionnaire comprised 24 items, covering a range of issues, each rated on 2 separate subscales of severity and satisfaction. Participants first rated the severity of each item on a Likert scale from 0 (worst) to 10 (best) and then rated their level of satisfaction in relation to each item on a separate Likert scale from 0 (not at all satisfied) to 10 (very satisfied). However, the length of the original CHOICE measure was a potential drawback, as participants were required to make 48 individual ratings, which may be a challenge for some people with psychosis where characteristic difficulties with concentration, motivation, and cognition may hamper completion.<sup>22,23</sup> Furthermore, there was a specific need for a measure that could be used to measure change over short time frames, including on a session-by-session basis, as part of the Improving Access to Psychological Therapies in Severe Mental Illness (IAPT-SMI) program. This study, therefore, aimed to develop a brief, psychometrically robust and clinically valuable version of CHOICE that would also be highly sensitive to change over a short (1 week) time frame. Initial development commenced, at the start of the IAPT-SMI program in 2013, and validation has subsequently been conducted across several distinct phases in a large sample of participants receiving psychological therapies.

## Methods

A total of 640 patients with psychosis experiences and severe mental illness (in receipt of secondary care services) contributed data in one of 2 phases: (1) the initial development or (2) the secondary validation of the CHOICE short form (CHOICE-SF).

## Development Phase

**Participants** The initial participants were 69 psychosis service users from the Psychological Interventions Clinic for outpatients with Psychosis (PICuP) run by the South London and Maudsley NHS Foundation Trust. They received CBTp according to NICE guidelines and provided full choice data at 2 time points: (1) an initial screening assessment (either prior to joining the waiting list [ $N = 45$ ] or immediately pretherapy [ $N = 24$ ]) and (2) post-CBTp. See Peters et al for further details about assessment procedures and therapy in PICuP.<sup>24</sup> A larger sample of 242 individuals with psychosis from PICuP, which included these 69 participants, completed the original full CHOICE measure on at least 1 of 5 time points (initial screening, immediately pretherapy, mid-therapy, posttherapy, or follow-up) and provided data for the initial factor analysis.

**Measures** Service users were asked to complete 5 measures as part of routine data collection by the clinic. All measures have good reliability and validity in a psychosis sample.

1. *The original CHOICE measure*<sup>12</sup>—a 24-item self-report questionnaire, which provides mean scores for severity and satisfaction with a range of aspects of psychological well-being, as well as additional self-reported items or therapy goals that are unique to the individual. Each item is reported on an 11-point scale from 0 (worst) to 10 (best). The mean score is used.
2. *The Beck Depression Inventory (BDI)*<sup>25</sup>—a 21-item measure of depressive symptoms and cognitions, on which each item is rated on a 4-point scale from 0 to 3 to produce a total score, from 0 to 63, where higher scores reflect more severe symptoms.
3. *The Beck Anxiety Inventory (BAI)*<sup>26</sup>—a 21-item measure of physiological anxiety symptoms, on which each item is rated on a 4-point scale from 0 (not at all) to 3 (severely) to produce a total score, from 0 to 63, where again high scores reflect more severe symptoms.
4. *The Manchester Assessment of Quality of Life (MANSA)*<sup>27</sup>—a 16-item measure that assesses satisfaction with life across 12 subjective measures and 4 objective measures, including areas, such as employment, finances, leisure, friendships, relationships, personal safety, accommodation, and physical and mental health. Each item is rated on a 7-point scale from 1 (could not be worse) to 7 (could not be better). The total score was used.
5. *The Psychotic Symptoms Rating Scale (PSYRATS)*<sup>28</sup>—which comprises a 17-item, 5-point (0–4) scale, multidimensional measure. The delusion scale comprises 6 items that capture distress, disruption, preoccupation, and conviction (scores range from 0 to 24). The Hallucinations Scale has 11 items that include

frequency, duration, loudness, location, intensity, distress, disruption, negative content, and beliefs about origin (scores range from 0 to 44).

A comparison group of 44 participants with a diagnosis of schizophrenia completed the full CHOICE at 2 time points 16 weeks apart as part of the treatment as usual control arm of a randomized trial conducted separately by our group.<sup>16</sup>

### Statistical Analysis

The severity and satisfaction scales of the original CHOICE measure are highly correlated. In the interests of developing a much briefer scale, only the CHOICE severity scale was selected as it is a simpler construct than satisfaction, which is impacted conceptually by the knowledge of opportunities and expectancies and methodologically by overlaps with health outcomes.<sup>29,30</sup> Cohen's *d* effect sizes were calculated to reflect the change on each of the individual items of the CHOICE measure using the pre-CBTp SD and mean difference pretherapy and posttherapy for the 69 participants who provided data pre- and post-CBTp. Items where the effect size was medium large (Cohen's *d* > 0.55) were retained, whilst those with smaller effect sizes (0.28 to 0.54) were omitted. Using this same sample of 69 participants, internal consistency (Cronbach's alpha) and sensitivity to change (one-way ANOVA) were also calculated, and specificity was confirmed by comparison with the 44 participants who provided full CHOICE data at 2 time points, from which the short form was derived, but who did not receive therapy. Construct validity was assessed by correlating pretherapy scores from the CHOICE-SF with the BDI, BAI, MANSA, and PSYRATS. The reliable change index (RCI)<sup>31–33</sup> and factor structure were also calculated in the whole sample of 242 participants, the latter using principal axis factoring. The Kaiser–Meyer–Olkin (KMO) value was 0.91, and the Bartlett's Test of Sphericity reached significance, thus supporting the suitability of the data for factor analysis. Sample sizes were large and greater than those reported for reliability and factor analysis in the original CHOICE paper. The single-factor, high-loading items, and communalities in the 0.5 range, together with >20–30 participants per item, provide sufficient power and a robust factor structure for both exploratory factor analysis (EFA) and Confirmatory factor analysis (CFA).<sup>34–36</sup> For the sensitivity analysis, a sample size calculation based on a medium pre–post effect size consistent with published literature (Cohen's *d* = 0.4) using a 2-sided paired *t*-test at the 5% alpha level and 80% power resulted in a minimum required sample size of *N* = 59.

### Secondary Validation Phase

**Participants** The factor structure of the CHOICE-SF was further examined using data provided by a further

354 transdiagnostic voice-hearing participants who attended an initial assessment at the Sussex Voices Clinic (a specialist outpatient service offered by Sussex Partnership NHS Foundation Trust) between May 2014 and June 2018 and completed the CHOICE-SF. Sensitivity to change of the CHOICE-SF was examined in 51 of these 354 participants who also completed the CHOICE-SF following at least 2–4 sessions of Coping Strategy Enhancement for voices<sup>37</sup> delivered by therapists with a range of expertise and either 8–12 sessions of group person-based cognitive therapy for distressing voices,<sup>16</sup> 6–16 sessions of individual relating and assertiveness therapy for voices,<sup>18</sup> or 6–8 sessions of individual guided self-help cognitive-behavioral intervention for distressing voices<sup>19</sup> delivered by expert therapists.

**Analysis** In the second validation phase, an a priori model of the questionnaire data was tested using confirmatory factor analysis based on a sample of *N* = 354 participants. The analysis was performed in the R software environment,<sup>38</sup> using the lavaan package,<sup>39</sup> and plots were created using lavaanPlot.<sup>40</sup> Full information maximum likelihood estimation was used in order to handle missing data points whilst improving bias and efficiency.<sup>41</sup> In addition to the chi-square test of exact fit, model fit was assessed using global and local fit indices: comparative fit index (CFI),<sup>42</sup> Tucker–Lewis index (TLI),<sup>43</sup> and goodness of fit index (GFI), as well as root mean square error of approximation (RMSEA)<sup>44</sup> and standardized root mean square residual (SRMR).<sup>45</sup> The magnitude and significance of factor loadings of the resulting model were also evaluated.

Two paired *t*-tests were then conducted to test the measure's sensitivity to change between baseline and follow-up: the first using the mean score of the 11 CHOICE-SF items and the second using the personal goal item alone. The personal goal item was analyzed separately as this item is personal to the individual and is not necessarily completed by all service users. Bayes factors were also calculated where possible as they enable a distinction between results that refute a hypothesis and those that reflect insufficient evidence, from which no conclusions can be drawn.<sup>46,47</sup>

## Results

### Development Phase

**Participants** Characteristics of the participants who took part in the development of the CHOICE-SF can be found in [table 1](#).

### Development of the Short Form

**Item Selection** Twelve out of 24 items had medium-large effect sizes (Cohen's *d* ranging from 0.55 to 0.77) for change with CBTp in the full (*N* = 69), and even larger effect sizes (Cohen's *d* ranging from 0.64 to 0.98) in the

**Table 1.** Characteristics of participants who took part in measure development and initial validation

	Initial item selection, sensitivity, and construct validity <i>N</i> = 69	Initial factor structure <i>N</i> = 242	Comparison sample <i>N</i> = 44
Age (mean and SD)	39 (8.29)	38 (9.44)	40 (10.87)
	<i>N</i> (%)	<i>N</i> (%)	<i>N</i> (%)
Gender			
Male	38 (55%)	142 (59%)	23 (52%)
Female	31 (45%)	100 (41%)	20 (46%) <sup>d</sup>
Marital status			
Single	55 (81%)	185 (82%)	25 (57%)
Married	6 (9%)	22 (10%)	8 (18%)
Divorced	4 (6%)	7 (3%)	6 (14%)
Other	3 (4%)	12 (5%)	4 (9%) <sup>e</sup>
Ethnicity			
White British/ English	37 (54%)	118 (49%)	40 (91%)
White Other	7 (10%)	19 (8%)	1 (2%)
Asian	2 (3%)	9 (4%)	1 (2%)
Black	16 (23%)	64 (27%)	2 (5%)
Chinese	0 (0%)	1 (0.4%)	—
Mixed	0 (0%)	0 (0%)	—
Other	7 (10%)	19 (8%)	—
Missing	0 (0%)	12 (5%)	—
Clinical characteristics			
Mean (SD; range)			
MANSA	48.1 (9.5; 23–68)	—	—
BDI <sup>a</sup>	23.7 (12.9; 3–53)	—	—
BAI <sup>a</sup>	19.2 (12.5; 0–50)	—	—
PSYRATS delusions <sup>b</sup>	14.6 (5.5; 0–22)	—	13.6 (5.5; 0–21) <sup>f</sup>
PSYRATS voices <sup>c</sup>	27.3 (9.3; 0–39)	—	29.8 (7.5; 0–38) <sup>g</sup>

Note: BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; PSYRATS, Psychotic Symptoms Rating Scale.

<sup>a</sup>*N* = 68.

<sup>b</sup>*N* = 45.

<sup>c</sup>*N* = 30.

<sup>d</sup>*N* = 43.

<sup>e</sup>*N* = 43.

<sup>f</sup>*N* = 25.

<sup>g</sup>*N* = 43.

smaller subsample (*N* = 24/69) with immediate pretherapy and posttherapy data. One of these items, “The ability to question the way I look at things,” overlapped conceptually with another, “The ability to see things from another point of view,” and internal consistency was found to be marginally greater (Cronbach’s  $\alpha$  = .93) with the former item. Therefore, only the first was included to provide a final CHOICE short-form measure (see [supplementary materials](#) for the final CHOICE-SF) comprising 11 items and 1 blank item for recording a personal goal.

**Internal Consistency, Construct Validity, and Sensitivity to Change** The final CHOICE-SF had high internal consistency (Cronbach’s  $\alpha$  = .93) and was highly sensitive to change with CBTp ( $df[68]$ ,  $t = -6.08$ ,  $P < .001$

[ $CI_{(95)} = -2.19$  to  $-1.10$ ]) with a large effect size for change (Cohen’s  $d = -0.84$  [ $CI_{(95)} = -1.15$  to  $-0.54$ ]). The same sensitivity and effect size calculations for the original full CHOICE in the same 69 participants yielded a slightly lower effect size ( $df[68]$ ,  $t = -5.56$ ,  $P < .001$  [ $CI_{(95)} = -1.98$  to  $-0.93$ ]; Cohen’s  $d = -0.73$  [ $CI_{(95)} = -1.03$  to  $-0.44$ ]). In contrast, and in support of the specificity of change to the intervention, the comparison group who received no intervention experienced no significant change on the CHOICE-SF ( $df[43]$ ,  $t = -1.09$ ,  $P = .28$  [ $CI_{(95)} = -1.09$  to  $0.20$ ]; Cohen’s  $d = -0.15$  [ $CI_{(95)} = -0.57$  to  $0.27$ ]).

Construct validity was good, with the CHOICE-SF mean score correlating positively with the MANSA ( $r = .70$ ,  $P < .001$ ) and negatively with the BDI ( $r = -.70$ ,  $P < .001$ ,

**Table 2.** Factor structure item loadings

Item	Initial sample factor loadings ( $N = 242$ )
1. The ability to approach problems in a variety of ways	0.59
2. Self-confidence	0.64
3. Positive ways of relating to people	0.69
4. The ability to question the way I look at things	0.64
5. Ways of dealing with everyday life stresses	0.67
6. Ways of dealing with a crisis	0.73
7. Facing my own upsetting thoughts and feelings	0.71
8. Peace of mind	0.71
9. Understanding myself and my past	0.70
10. Understanding my experiences	0.73
11. Positive ways of thinking	0.81

$N = 68$ ) and BAI ( $r = -.52$ ;  $P < .001$ ;  $N = 68$ ). However, the CHOICE-SF did not correlate with the PSYRATS delusions ( $r = -.277$ ,  $P = .069$ ,  $N = 45$ ) or voices scales ( $r = -.313$ ,  $P = .098$ ,  $N = 30$ ). These findings are consistent with and stronger than those for the original CHOICE measure where the severity scale correlated significantly with the MANSA ( $r = .52$ ), BDI ( $r = -.70$ ), BAI ( $r = -.48$ ), distress/disruption items on the PSYRATS ( $r = -.26$ – $.28$ ) but not with traditional PSYRATS symptom measures of conviction with delusions ( $r = .11$ ) or frequency, location, or beliefs about voices ( $r = .01$ – $.10$ ).<sup>12</sup>

**Initial Factor Analysis** Following item selection, internal consistency, validity, and sensitivity analysis, a principal axis factoring analysis was conducted on a larger sample of 242 participants. This revealed a single factor with an eigenvalue exceeding 1, which explained 52.3%, of the variance. The factor loadings are presented in table 2.

**The RCI** The RCI<sup>31–33</sup> for CHOICE-SF was calculated for items 1–11 only (as the goal item is not used by all service users) using the SD (1.983) from the full 242 participant sample. The RCI was found to be 1.45, indicating that a change in the mean score of 1.45 points or more is considered a statistically reliable change. This compares to the RCI derived from the SD (1.93) and reliability (0.83) of the original CHOICE questionnaire<sup>12</sup> of 2.2 points. With regards to the initial development sample ( $N = 69$ ), 82% of this sample demonstrated some improvement, ie, an increase in total score on the CHOICE-SF following CBTp and over half of the participants (53%) showed a statistically reliable improvement of at least 1.45 points on the CHOICE-SF.

### Secondary Validation of the Short Form

**Participants** The characteristics of participants who took part in the secondary validation can be found in table 3.

**Table 3.** Characteristics of participants who took part in the secondary validation

	Baseline sample used for confirmatory factor analysis ( $N = 354$ )	Completers of therapy ( $N = 51$ )
	$M$ (SD: range)	$M$ (range)
Age	37 (13.1: 13–69) <sup>a</sup>	41 (11.5: 19–67)*
	$N$ (%)	$N$ (%)
Gender		
Male	164 (46%)	25 (50%)
Female	191 (53%)	26 (50%)
Other	2 (1%)	
Employment		
Employed	64 (18%)	7 (14%)
Unemployed	240 (67%)	39 (76%)
Student	28 (8%)	4 (8%)
Missing	26 (7%)	1 (2%)
Ethnicity		
White British	293 (82%)	39 (76%)
White Other	21 (6%)	6 (11%)
Asian	9 (3%)	
Black	8 (2%)	3 (5%)
Chinese	2 (1%)	1 (2%)
Mixed	12 (3%)	2 (5%)
Other	8 (2%)	
Missing	4 (1%)	
Diagnosis <sup>b</sup>		
Schizophrenia	105 (29%)	19 (36%)
Schizoaffective	16 (5%)	5 (11%)
Borderline/unstable personality disorder	62 (17%)	8 (16%)
Complex trauma	1 (0.1%)	0 (0%)
Depression	20 (6%)	7 (13%)
Mixed	70 (20%)	9 (18%)
Other	44 (12%)	1 (2%)

<sup>a</sup> $N = 349$  for age.

<sup>b</sup> $N = 352$  for diagnosis.

\*Significant difference in age between those who completed therapy and the remainder of the baseline sample ( $df[347]$ ,  $t = -2.0$ ,  $P = .044$  [ $CI_{95} = 7.93$  to  $-0.11$ ]). There were no other significant differences in clinical or demographic characteristics between groups.

**Secondary Factor Analyses** For the CFA model of a single “Psychological Recovery” factor with 11 indicators, the chi-square test was significant,  $\chi^2 = 175.408$ ,  $df = 44$ ,  $P < .001$ , as can occur in smaller data sets. Other fit indices suggested a good or acceptable level of approximate fit: CFI = 0.942, TLI = 0.942, GFI = 0.953, RMSEA = 0.092,  $CI_{(90)} = 0.076$ ; 0.106, and SRMR = 0.042. In order to evaluate potential errors of model specification, the standardized residuals matrix was evaluated as suggested by Kline.<sup>48</sup> Two adjacent items (Q9: understanding myself and my past; Q10: understanding my experiences) were found to have a high ( $>|.10|$ ) residual.

The CFA model allowing for correlated errors between Q9 and Q10 improved model fit resulting in a lower but

**Table 4.** Unstandardized (est) and standardized (std) estimates of factors loadings, with SE, significance (*P*), and variance explained (var), for the confirmatory factor analysis

Questionnaire item	Est	SE	<i>P</i>	Std
1. The ability to approach problems in a variety of ways	1			0.731
2. Self-confidence	1.052	0.076	<.001	0.771
3. Positive ways of relating to people	1.002	0.082	<.001	0.681
4. The ability to question the way I look at things	1.123	0.085	<.001	0.730
5. Ways of dealing with everyday life stresses	1.062	0.072	<.001	0.815
6. Ways of dealing with a crisis	1.191	0.083	<.001	0.794
7. Facing my own upsetting thoughts and feelings	1.023	0.077	<.001	0.740
8. Peace of mind	0.938	0.075	<.001	0.700
9. Understanding myself and my past	1.118	0.092	<.001	0.676
10. Understanding my experiences (eg, beliefs, thoughts, voices, and related feelings)	1.007	0.084	<.001	0.667
11. Positive ways of thinking	1.018	0.075	<.001	0.753

significant chi-square value,  $\chi^2 = 92.124$ ,  $df = 43$ ,  $P < .001$ . Other indices also suggested an improved fit compared to the previous model, CFI = 0.978, TLI = 0.972, GFI = 0.975. RMSEA = 0.057,  $CI_{(90)} = 0.041$ ; 0.073 allowing the rejection of the poor-fit hypothesis ( $<.10$ ). The SRMR also decreased and was below the value of 0.08, SRMR = 0.029. All factor loadings (ranging from 0.667 and 0.815) were significant indicators of psychological recovery as displayed below in [table 4](#). *Secondary Sensitivity to Change* The *t*-tests assessing sensitivity to change again revealed a significant difference between baseline and posttherapy mean score for the CHOICE-SF (11 items; ( $df[50]$ ),  $t = 5.34$ ,  $P < .001$  [ $CI_{(95)} = 2.04-0.92$ ], Bayes factor = 38 614). A larger significant difference was found for the personal goal item ( $df[53]$ ),  $t = 7.93$ ,  $P < .0001$ , [ $CI_{(95)} = 2.19-3.67$ ], Bayes factor = 846). Bayes factors were greater than 100, which demonstrates that these effects are strong evidence of change over time with CBTp.<sup>47</sup>

## Discussion

We aimed to develop and validate a short version of the CHOICE measure for use in research and clinical practice, with a specific view to it being sensitive and suitable for use over short time scales and on a sessional basis. A 1-page version (CHOICE-SF) was developed from the original severity scale, containing 11 items + 1 personal goal, which retained a clear single-factor structure, was highly sensitive to change and showed high internal consistency, validity, and utility for research and clinical practice as evidenced by its already rapid adoption in a broad range of contexts.<sup>11,49-64</sup>

The CHOICE-SF continues to incorporate both cognitive and coping outcomes that are amenable to change with CBTp, as well as well-being outcomes, such as peace of mind. The single-factor structure was stable across 2 data sets from different clinics in different mental health services. It correlated closely with affect and quality of life but not delusions and voices measures and, as such, supports its discriminant validity from positive symptom measures.

Since the development of the CHOICE-SF, it has already been used in 6 recent or on-going trials,<sup>11,49-53</sup> 3 pilot-feasibility studies,<sup>54-56</sup> 2 case studies,<sup>57,58</sup> 1 case series,<sup>59</sup> and 5 observational studies.<sup>60-64</sup> However, as noted by Stevens et al,<sup>64</sup> no psychometric properties have been available for this short form. Fornells-Ambroio et al<sup>61</sup> used the CHOICE-SF at every session in an IAPT-SMI demonstration site for people with psychosis. The authors found that the CHOICE-SF was well received, with 71% ( $N = 64$ ) of clients surveyed at the end of therapy reporting it to be actively helpful. Qualitative analysis found that using the CHOICE-SF was helpful for monitoring improvements, although it could be less helpful when progress was not being made. Furthermore, the goal-setting item in the CHOICE-SF was particularly valued by service users.<sup>61</sup> In a further paper from the same IAPT-SMI site, the authors reported that paired completion rates, ie, a minimum of 2 CHOICE-SF being completed over the course of therapy, were high at 97%.<sup>60</sup> Interestingly, this paper also showed that 77% of patients showed some improvement in CHOICE score following CBTp and 55% showed significant reliable change. These figures are highly consistent with those reported in the current paper where 82% of participants showed some improvement and 53% showed reliable change. These studies show that the CHOICE-SF can be implemented and is acceptable and successful in demonstrating reliable change as a routine outcome measure. It can be used within clinical services, including in an IAPT-SMI demonstration site, and in research trials that evaluate psychological therapies for a range of issues, including paranoia, sleep, worry, and self-confidence.

The study has several strengths. We have validated the psychometric properties in 2 transdiagnostic participant populations, one incorporating psychosis symptoms and the other being voice hearers specifically, with different gender distribution. This demonstrates that the measure is valid and sensitive to change in a mixed sample of people with severe mental illness, including borderline and emotionally unstable personality disorders, complex trauma, and depression, as well as psychosis. Furthermore, people from black Caribbean or African populations are 2.4-14.4 times more likely to develop psychosis compared to other ethnic groups.<sup>65,66</sup> This ethnic variation is captured in the initial sample where 26% of service users were black Caribbean or African, suggesting that the CHOICE-SF can be used across a mixed, heterogeneous population. It has similar internal consistency and validity, but enhanced

sensitivity to change compared to the original measure, and facilitates a focus on other aspects of change besides positive symptom. It retains a personal goal item, which is liked by service users, valuable in shaping therapy focus, and particularly sensitive to change. Although we have not directly compared acceptability and ease of use between CHOICE and CHOICE-SF, the latter is much shorter and simpler to complete and score, comprising only one subscale, making it highly valuable for use in research and routine clinical services.

In terms of limitations, the initial item selection, internal consistency, and construct validity of the CHOICE-SF were calculated in a comparatively small sample. Item selection was informed by effect sizes, which are not influenced by sample size, and, although small samples can lead to biases in sample selection, the current study utilized an unselected heterogeneous clinical sample, with high ecological validity. The sample size may have contributed to the lack of a significant correlation with psychosis symptoms in contrast to the quality of life and emotional symptoms. The low correlation values with psychosis symptoms are, however, in line with the recovery and CBTp literature and with our previous study, where psychosis symptoms are not necessarily related to well-being or to important CBTp outcomes. Black African and Caribbean service users were slightly underrepresented in the secondary validation sample (2% compared to 3% in the general population)<sup>67</sup> with some underrepresentation of Asian populations in both samples (general population = 6.9% vs initial validation = 2.90% and baseline secondary validation sample = 4%).

## Conclusions

The CHOICE-SF is an 11-item patient-reported service-user-led psychological recovery outcome measure with high validity, internal consistency, and sensitivity to change, with an additional item for a personal goal, which has been found to be highly regarded by service users.<sup>61</sup> It is applicable to a broad and heterogeneous service user population and can be employed on a session-by-session basis to evaluate psychological therapy outcomes for severe mental illness.

## Supplementary Material

Supplementary material is available at *Schizophrenia Bulletin*.

## Acknowledgments

The authors have declared that there were no financial conflicts of interest in relation to the subject of this study.

## Funding

This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

## Ethical Standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975 as revised in 2008.

## References

1. National Institute for Health and Care Excellence. *Implementing the Early Intervention in Psychosis Access and Waiting Time Standard: Guidance*. NHS England, National Collaborating Centre for Mental Health; 2016. <https://www.nice.org.uk/guidance/qs80/resources/implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard-guidance-2487749725>.
2. Bighelli I, Salanti G, Huhn M, et al. Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. *World Psychiatry*. 2018;17(3):316–329.
3. Birchwood M, Trower P. The future of cognitive-behavioural therapy for psychosis: not a quasi-neuroleptic. *Br J Psychiatry*. 2006;188:107–108.
4. Byrne RE. CBT for psychosis: not a “quasi-neuroleptic.” *Br J Psychiatry*. 2014;204(6):489.
5. Garety PA, Bebbington P, Fowler D, Freeman D, Kuipers E. Implications for neurobiological research of cognitive models of psychosis: a theoretical paper. *Psychol Med*. 2007;37(10):1377–1391.
6. Morrison A, Renton J, French P, Bentall RP. *Think You're Crazy? Think Again: A Resource Book for Cognitive Therapy for Psychosis*. Hove, UK: Routledge; 2008.
7. Perkins R. What constitutes success? The relative priority of service users' and clinicians' views of mental health services. *Br J Psychiatry*. 2001;179:9–10.
8. Iqbal Z, Birchwood M, Chadwick P, Trower P. Cognitive approach to depression and suicidal thinking in psychosis. 2. Testing the validity of a social ranking model. *Br J Psychiatry*. 2000;177:522–528.
9. Gumley A, O'Grady M, McNay L, Reilly J, Power K, Norrie J. Early intervention for relapse in schizophrenia: results of a 12-month randomized controlled trial of cognitive behavioural therapy. *Psychol Med*. 2003;33(3):419–431.
10. Hall PL, Tarrow N. The cognitive-behavioural treatment of low self-esteem in psychotic patients: a pilot study. *Behav Res Ther*. 2003;41(3):317–332.
11. Freeman D, Pugh K, Dunn G, et al. An early Phase II randomised controlled trial testing the effect on persecutory delusions of using CBT to reduce negative cognitions about the self: the potential benefits of enhancing self confidence. *Schizophr Res*. 2014;160(1–3):186–192.
12. Greenwood KE, Sweeney A, Williams S, et al. CHOICE of Outcome In Cbt for psychosEs (CHOICE): the development of a new service user-led outcome measure of CBT for psychosis. *Schizophr Bull*. 2010;36(1):126–135.
13. Priebe S, Kelley L, Golden E, et al. Effectiveness of structured patient-clinician communication with a solution focused approach (DIALOG+) in community treatment of patients with psychosis—a cluster randomised controlled trial. *BMC Psychiatry*. 2013;13:173.
14. Priebe S, Golden E, Kingdon D, et al. *Effective Patient–Clinician Interaction to Improve Treatment Outcomes*

- for Patients With Psychosis: A Mixed-Methods Design. Southampton, UK: NIHR Journals Library; 2017.
15. Lecomte T, Leclerc C, Wykes T, Nicole L, Abdel Baki A. Understanding process in group cognitive behaviour therapy for psychosis. *Psychol Psychother*. 2015;88(2):163–177.
  16. Chadwick P, Strauss C, Jones AM, et al. Group mindfulness-based intervention for distressing voices: a pragmatic randomised controlled trial. *Schizophr Res*. 2016;175(1–3):168–173.
  17. Lincoln TM, Jung E, Wiesjahn M, Schlier B. What is the minimal dose of cognitive behavior therapy for psychosis? An approximation using repeated assessments over 45 sessions. *Eur Psychiatry*. 2016;38:31–39.
  18. Hayward M, Jones AM, Bogen-Johnston L, Thomas N, Strauss C. Relating therapy for distressing auditory hallucinations: a pilot randomized controlled trial. *Schizophr Res*. 2017;183:137–142.
  19. Hazell CM, Hayward M, Cavanagh K, Jones AM, Strauss C. Guided self-help cognitive-behaviour Intervention for VoiceS (GiVE): results from a pilot randomised controlled trial in a transdiagnostic sample. *Schizophr Res*. 2018;195:441–447.
  20. Cooke A, Basset T, Bentall R, et al. *Understanding Psychosis and Schizophrenia: Why People Sometimes Hear Voices, Believe Things That Others Find Strange, or Appear Out of Touch With Reality, and What Can Change*. Leicester, UK: Division of Clinical Psychology, The British Psychological Society; 2017.
  21. Lincoln T. *Kognitive Verhaltenstherapie der Schizophrenie: Ein Individuenzentrierter Ansatz*. Gottingen, Germany: Hogrefe Verlag; 2014.
  22. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders: DSM-5*. Arlington, VA: American Psychiatric Association; 2014.
  23. Wood H, Cupitt C, Lavender T. The experience of cognitive impairment in people with psychosis. *Clin Psychol Psychother*. 2015;22(3):193–207.
  24. Peters E, Crombie T, Agbedjro D, et al. The long-term effectiveness of cognitive behavior therapy for psychosis within a routine psychological therapies service. *Front Psychol*. 2015;6:1658.
  25. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961;4:561–571.
  26. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. *J Consult Clin Psychol*. 1988;56(6):893–897.
  27. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). *Int J Soc Psychiatry*. 1999;45(1):7–12.
  28. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). *Psychol Med*. 1999;29(4):879–889.
  29. Williams B. Patient satisfaction: a valid concept? *Soc Sci Med*. 1998;38:509–516.
  30. Meredith P. But was the operation worth it? The limitations of quality of life and patient satisfaction research in health-care outcome assessment. *J Qual Clin Pract*. 1996;16(2):75–85.
  31. Christensen L, Mendoza JL. A method of assessing change in a single subject: an alteration of the RC index. *Behav Ther*. 1986;17:305–308.
  32. Evans C. *Reliable change criterion calculator*. <https://www.psycht.org/cgi-bin/rcsc1.prl>. Accessed September 17, 2020.
  33. Evans C. *Reliable and clinically significant change*. <https://www.psycht.org/stats/rcsc.htm>. Accessed September 17, 2020.
  34. MacCallum RC, Widaman KF, Zhang S, Hong S. Sample size in factor analysis. *Psychol Methods*. 1999;4:84–99.
  35. Tabachnick BG, Fidell LS. *Using Multivariate Statistics. Chapter 13*. 4th ed. New York, NY: Harper Collins; 2001.
  36. Wolf EJ, Harrington KM, Clark SL, Miller MW. Sample size requirements for structural equation models: an evaluation of power, bias, and solution propriety. *Educ Psychol Meas*. 2013;76(6):913–934.
  37. Tarrier N, Harwood S, Yusopoff L, Beckett R, Baker A. Coping strategy enhancement (CSE): a method of treating residual schizophrenic symptoms. *Behav Cogn Psychother*. 1990;18:283–293.
  38. R Core Team. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing; 2013.
  39. Rosseel Y. lavaan: an R package for structural equation modeling. *J Stat Softw*. 2012;48(2):1–36.
  40. Lishinski A. lavaanPlot: path diagrams for lavaan models via DiagrammeR. R Package Version 0.5. 1. 2018. <https://cran.r-project.org/web/packages/lavaanPlot/lavaanPlot.pdf>. Accessed September 16, 2020.
  41. Enders CK, Bandalos DL. The relative performance of full information maximum likelihood estimation for missing data in structural equation models. *Struct Equ Modeling*. 2001;8(3):430–457.
  42. Bentler PM. Comparative fit indexes in structural models. *Psychol Bull*. 1990;107(2):238–246.
  43. Tucker LR, Lewis C. A reliability coefficient for maximum likelihood factor analysis. *Psychometrika*. 1973;38(1):1–10.
  44. Browne MW, Cudeck R. Alternative ways of assessing model fit. *Soc Methods Res*. 1992;21(2):230–258.
  45. Bentler PM. *EQS Structural Equations Program Manual*. Encino, CA: Multivariate Software; 1995.
  46. Dienes Z. *Understanding Psychology as a Science: An Introduction to Scientific and Statistical Inference*. Basingstoke, UK: Palgrave Macmillan; 2008.
  47. Lee MD, Wagenmakers EJ. *Bayesian Modeling for Cognitive Science: A Practical Course*. Cambridge, UK: Cambridge University Press; 2009.
  48. Kline RB. *Principles and Practice of Structural Equation Modeling*. 4th ed. New York, NY: The Guilford Press; 2016.
  49. Freeman D, Dunn G, Startup H, et al. Effects of cognitive behaviour therapy for worry on persecutory delusions in patients with psychosis (WIT): a parallel, single-blind, randomised controlled trial with a mediation analysis. *Lancet Psychiatry*. 2015;2(4):305–313.
  50. Freeman D, Waite F, Startup H, et al. Efficacy of cognitive behavioural therapy for sleep improvement in patients with persistent delusions and hallucinations (BEST): a prospective, assessor-blind, randomised controlled pilot trial. *Lancet Psychiatry*. 2015;2(11):975–983.
  51. Freeman D, Waite F, Emsley R, et al. The efficacy of a new translational treatment for persecutory delusions: study protocol for a randomised controlled trial (The Feeling Safe Study). *Trials*. 2016;17(1):134.
  52. Freeman D, Lister R, Waite F, et al. Automated psychological therapy using virtual reality (VR) for patients with persecutory delusions: study protocol for a single-blind parallel-group randomised controlled trial (THRIVE). *Trials*. 2019;20(1):87.
  53. Jolley S, Browning S, Corrigan R, et al. Coping with Unusual Experiences for 12–18 year olds (CUES+): a transdiagnostic randomised controlled trial of the effectiveness of cognitive therapy in reducing distress associated with

- unusual experiences in adolescent mental health services: study protocol for a randomised controlled trial. *Trials*. 2017;18(1):586.
54. Husain N, Gire N, Kelly J, et al. TechCare: mobile assessment and therapy for psychosis—an intervention for clients in the Early Intervention Service: a feasibility study protocol. *SAGE Open Med*. 2016;4:1–9.
  55. Waller H, Landau S, Fornells-Ambrojo M, et al. Improving implementation of evidence based practice for people with psychosis through training the wider workforce: results of the GOALS feasibility randomised controlled trial. *J Behav Ther Exp Psychiatry*. 2018;59:121–128.
  56. Greenwood K, Alford K, O’Leary I, et al. The U&I study: study protocol for a feasibility randomised controlled trial of a pre-cognitive behavioural therapy digital ‘informed choice’ intervention to improve attitudes towards uptake and implementation of CBT for psychosis. *Trials*. 2018;19(1):644.
  57. Ward-Brown J, Keane D, Bhutani G, et al. TF-CBT and EMDR for young people with trauma and first episode psychosis (using a phasic treatment approach): two early intervention service case studies. *Cogn Behav Ther*. 2018;11:e17.
  58. McCartney L, Douglas M, Varese F, et al. Cognitive behavioural therapy for psychosis targeting trauma, voices and dissociation: a case report. *Cogn Behav Ther*. 2019;12:e18.
  59. Courtney H, White L, Richardson T, et al. Impact of a brief worry-based cognitive therapy group in psychosis: a study of feasibility and acceptability. *Cogn Behav Ther*. 2019;12:e29.
  60. Jolley S, Garety P, Peters E, et al. Opportunities and challenges in Improving Access to Psychological Therapies for people with Severe Mental Illness (IAPT-SMI): evaluating the first operational year of the South London and Maudsley (SLaM) demonstration site for psychosis. *Behav Res Ther*. 2015;64:24–30.
  61. Fornells-Ambrojo M, Johns L, Onwumere J, et al. Experiences of outcome monitoring in service users with psychosis: findings from an Improving Access to Psychological Therapies for people with Severe Mental Illness (IAPT-SMI) demonstration site. *Br J Clin Psychol*. 2017;56(3):253–272.
  62. Hayward M, Edgecumbe R, Jones AM, Berry C, Strauss C. Brief coping strategy enhancement for distressing voices: an evaluation in routine clinical practice. *Behav Cogn Psychother*. 2018;46(2):226–237.
  63. Paulik G, Jones AM, Hayward M. Brief coping strategy enhancement for distressing voices: predictors of engagement and outcome in routine clinical practice. *Clin Psychol Psychother*. 2018;25(5):634–640.
  64. Stevens J, Butterfield C, Whittington A, Holttum S. Evaluation of arts based courses within a UK recovery college for people with mental health challenges. *Int J Environ Res Public Health*. 2018;15(6):1170.
  65. Harrison G, Glazebrook C, Brewin J, et al. Increased incidence of psychotic disorders in migrants from the Caribbean to the United Kingdom. *Psychol Med*. 1997;27(4):799–806.
  66. Kirkbride JB, Barker D, Cowden F, et al. Psychoses, ethnicity and socio-economic status. *Br J Psychiatry*. 2008;193(1):18–24.
  67. Office for National Statistics. *2011 Census: Ethnic Group, Local Authorities in the United Kingdom*. London, UK: Office for National Statistics; 2013.